Key result
Direct thrombin and factor Xa inhibitors are compared with traditional VKA antagonists for the treatment and prevention of venous thromboembolism in this review of recent clinical trials.
Why the study?
Venous thromboembolism is a major burden in clinical practice as one of the most frequent causes of cardiovascular death and disabling embolic stroke worldwide.
The article highlights the burden of the venous thromboembolism (VTE) in clinical practice as one of the most frequent cause of cardiovascular death and disabling embolic stroke worldwide. The author compares the traditional use of VKA antagonists and new class of oral anticoagulants — direct thrombin and factor Xa inhibitors for VTE treatment and prevention. The results of most significant randomized clinical trials in VTE area and latest international guidelines are also discussed.
No takes yet. Share an insight, caveat, or question.
V. I. Shalnev (2018) conducted a review in Venous thromboembolism (VTE). Direct thrombin and factor Xa inhibitors vs. VKA antagonists was evaluated. Direct thrombin and factor Xa inhibitors are compared with traditional VKA antagonists for the treatment and prevention of venous thromboembolism in this review of recent clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: